TOKYO–(BUSINESS WIRE)–HOYA Corporation (TOKYO:7741) today announced financial results for the fourth quarter and full-year ended March 31, 2016. During the quarter, revenues decreased by 4.5% to 121,666 million yen year on year. Pre-tax profit for th…
Category: Business
Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today that the company initiated a phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT02753400) with the successful enrollment of the first patient, to assess the benefits of emixustat hydrochloride (emixustat) for the treatment of pro
Lumenis to Present Interim Safety and Efficacy Results of IPL with OPT™ for Treating Dry Eye at Major Ophthalmology Meeting
YOKNEAM, Israel–(BUSINESS WIRE)–ASCRS Booth #2311– Lumenis, Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, will present interim results of a multicenter prospective clinical trial designed to study the safety and efficacy of Optimal Pulse Technology (OPTTM), the next generation of Intense Pulse Light (IPL) technology, for treating Dry Eye Disease (DED). Data from the trial, being led by Steven J. Dell, MD, of Dell Laser Cons
RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences
ANN ARBOR, Mich.–(BUSINESS WIRE)–CEO Sean Ainsworth will highlight RetroSense’s contributions to gene therapy research during panel presentations at the NY BIO 2016 Annual Meeting and the Piper Jaffray GenomeRx Symposium.
Global Glaucoma Market 2016 – Valuations, Analysis & Forecast – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Glaucoma Market and Competitive Landscape Highlights – 2016” report to their offering. The latest research report provides comprehensive insights into pipeline prod…
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2016, at 2:20 p.m. Pacific Time in Las Vegas. A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.ac
Isarna Presents First Interim Phase I Data for ISTH0036 in Advanced Glaucoma at ARVO 2016 Annual Conference
MUNICH–(BUSINESS WIRE)–Isarna Presents First Interim Phase I Data for ISTH0036 in Advanced Glaucoma at ARVO 2016 Annual Conference
Salutaris Medical Devices™ „Distance of Choroid Study” zu feuchter AMD im Rahmen der ARVO 2016 präsentiert
SEATTLE–(BUSINESS WIRE)–Heute wurden neue Ergebnisse der Distance of Choroid Study (DOCS-Studie) der Salutaris Medical Devices, Inc. (SalutarisMD®) zu feuchter AMD (altersabhängige Makuladegeneration) im Rahmen von zwei Präsentationen auf der Jahresversammlung der Association for Research in Vision and Ophthalmology, Inc. (ARVO) präsentiert. Das erste wissenschaftliche Poster von Dr. Kamaljit Balaggan präsentierte klinische Ergebnisse, die über eine geplante interventionelle Studie informiere
Salutaris Medical Devices™ wet AMD Distance of Choroid Study Presented at ARVO 2016
SEATTLE–(BUSINESS WIRE)–Today results from the Salutaris Medical Devices, Inc. (SalutarisMD®) wet age-related Macular Degeneration (wet AMD) Distance of Choroid Study (DOCS) were featured in two presentations at the Association for Research in Vision and Ophthalmology, Inc. (ARVO) Annual Meeting. The first poster, by Dr. Kamaljit Balaggan, presented clinical results informing an upcoming interventional study employing the SalutarisMD® novel episcleral brachytherapy device for treatment of wet
Glaukos Corporation Announces First Quarter 2016 Financial Results
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Ocular Therapeutix™ to Report First Quarter 2016 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report f…
Europe Uveitis Market Report 2016-2020 – Analysis, Technologies & Forecasts – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Europe Uveitis Market and Competitive Landscape Highlights – 2016” report to their offering. The latest research Europe Uveitis Market and Competitive Landscape Highlights…
Osterhout Design Group Teams with NuEyes for Solution to Help Those with Low Vision
SAN FRANCISCO–(BUSINESS WIRE)–NuEyes and Osterhout Design Group announced the availability of portable head-worn devices that can re-open the wearer’s eyes to a world they believed forever lost due to failing sight.
Ora®がデビッド・ホランダー医師（M.D.、M.B.A.）を最高医学責任者（CMO）に任命
ボストン–(BUSINESS WIRE)–（ビジネスワイヤ） — 眼科用医薬品・医療機器の開発における世界一流パートナーのOra, Inc.は本日、デビッド・A・ホランダー医師（M.D.、M.B.A.）を最高医学責任者（CMO）兼シニアバイスプレジデントに任命したと発表しました。ホランダー医師は最近までアラガンの治療領域責任者兼臨床開発担当バイスプレジデントを務め、前眼部疾患とコンシューマーアイケアの分野における世界戦略および臨床開発プログラムの責任を負っていました。 Oraの社長兼最高経営責任者（CEO）であるスチュアート・B・エーブルソンは、次のように述べています。「Oraの技術、業務手法、有能なチームが、当社がその卓越性の評価を確立する上で極めて重大な役割を果たしてきました。ホランダー医師がOraにもたらす視点、経験、スキルは、当社顧客の大小の開発プログラムのあらゆる段階に対し格別の価値を提供する当社の能力を強化するものです。」 ハーバード大学眼科教授で外科医のマーク・エーブルソン医師が創設したOraが35年以上にわたり使命としているのは、眼科における臨床研究の質と再現性
Ora® nomeia Dr. David Hollander, mestre em Administração de Negócio, como diretor médico
BOSTON, EUA–(BUSINESS WIRE)–Ora, Inc., a principal parceira mundial de desenvolvimento farmacêutico e de dispositivos oftalmológicos, anunciou hoje a nomeação do Dr. David A. Hollander, mestre em Administração de Negócio (M.B.A.), como diretor médico e vice-presidente sênior. Dr. Hollander trabalhou recentemente como diretor da área terapêutica e vice-presidente de desenvolvimento clínico na Allergan®, responsável pelos programas estratégicos globais e de desenvolvimento clínico no segmento o
Ora® designa a David Hollander, M.D., M.B.A., como Director Médico Ejecutivo
BOSTON–(BUSINESS WIRE)–Ora, Inc., el socio líder mundial de los productos farmacéuticos oftalmológicos y desarrollo de dispositivos, anunció hoy la designación de David A. Hollander, M.D., M.B.A., como Director Médico Ejecutivo y Vicepresidente Ejecutivo. El Dr. Hollander recientemente se desempeñó como Director del Área Terapéutica y Vicepresidente de desarrollo clínico en Allergan®, responsable de los programas de estrategia global y desarrollo clínico en oftalmología del segmento anterior
Ora® nomme David Hollander, M.D., M.B.A., des services médicaux
BOSTON–(BUSINESS WIRE)–Ora, Inc., le principal partenaire mondial pour le développement de dispositifs et produits pharmaceutiques ophtalmiques, a annoncé aujourd’hui la nomination de David A. Hollander, M.D., M.B.A., au poste de chef des services médicaux et premier vice-président. Le Dr Hollander a récemment servi comme chef du domaine thérapeutique et vice-président du développement clinique à Allergan®, responsable de la stratégie globale et des programmes de développement clinique dans l
Ora® ernennt Dr. med. David Hollander, M.B.A., zum Chief Medical Officer
BOSTON–(BUSINESS WIRE)–Ora, Inc., der weltweit führende Partner bei der Entwicklung von augenheilkundlichen pharmazeutischen und technischen Produkten, meldete heute die Ernennung von Dr. med. David A. Hollander, M.B.A., zum Chief Medical Officer und Senior Vice-President. Dr. Hollander war zuletzt Therapeutic Area Head und Vice President für klinische Entwicklung bei Allergan® und in dieser Stellung für die globale Strategie und klinischen Entwicklungsprogramme in der Ophthalmologie des vord
Riassunto: Ora® sceglie il Dr. David Hollander, M.B.A., come direttore medico
BOSTON–(BUSINESS WIRE)–Ora, Inc., il principale partner mondiale per lo sviluppo di dispositivi e prodotti farmaceutici nel settore oftalmico, ha oggi annunciato la nomina a vicepresidente senior e direttore medico del dottor David A. Hollander, M.B.A. Negli ultimi anni il Dr. Hollander ha ricoperto la carica di responsabile del settore terapeutico e di vicepresidente dello sviluppo clinico presso Allergan®, in qualità di responsabile della strategia globale e dei programmi di sviluppo clinic
Ora® Appoints David Hollander, M.D., M.B.A., as Chief Medical Officer
BOSTON–(BUSINESS WIRE)–Ora® APPOINTS DAVID HOLLANDER, M.D., M.B.A., AS CHIEF MEDICAL OFFICER